SCHEMBL6014596

SCHEMBL6014596

CCOC(=O)c1ccccc1NCc1ccncc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.61
ADRA1A P35348 1/20 0.61
ADRA1B P35368 1/20 0.61
ALDH1A1 P00352 1/20 0.56
ADRA2C P18825 1/20 0.56
HSD17B10 Q99714 3/20 0.54
KDM4E B2RXH2 2/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 5/20 0.53
NPSR1 Q6W5P4 2/20 0.52
RAB9A P51151 1/20 0.52
KDR P35968 2/20 0.52
FLT1 P17948 1/20 0.52
CDC7 O00311 1/20 0.52
DBF4 Q9UBU7 1/20 0.52
MAPK10 P53779 1/20 0.51
KMT2A Q03164 2/20 0.50
LMNA P02545 1/20 0.50
CDC25A P30304 1/20 0.50
CDC25B P30305 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11170835 0.89 NPSR1 (0.60) ADRA1DADRA1AADRA1BALDH1A1HSD17B10
SCHEMBL1714816 0.87 ALDH1A1 (0.71) ADRA1DADRA1AADRA1BALDH1A1ADRA2C
SCHEMBL20379211 0.85 ALDH1A1 (0.80) ALDH1A1HSD17B10KDM4ETP53TSHR
SCHEMBL2087718 0.84 KDM4C (0.69) ADRA1DADRA1AADRA1BALDH1A1HSD17B10
SCHEMBL13279708 0.84 KDM4E (0.64) ADRA1DADRA1AADRA1BHSD17B10KDM4E
SCHEMBL10771374 0.84 MAPT (0.62) ADRA1DADRA1AADRA1BALDH1A1HSD17B10
SCHEMBL11501726 0.82 KDM4E (0.55) ADRA1DADRA1AADRA1BALDH1A1HSD17B10
SCHEMBL14855780 0.82 KDM4E (0.64) ADRA1DADRA1AADRA1BALDH1A1HSD17B10
SCHEMBL28236466 0.82 KDR (0.62) NPSR1RAB9AKDRCDC7DBF4
SCHEMBL1714827 0.81 ALDH1A1 (0.53) ADRA1DADRA1AADRA1BALDH1A1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP disclosed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US disclosed
EP-1633712-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Chen, Guoqing Paul (US) 2006-03-15 EP disclosed
WO-2005000232-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2005-01-06 WO disclosed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US disclosed
WO-2004052280-A2 ANTI-ANGIOGENIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT IMCLONE SYSTEMS INCORPORATED (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors TEK, FLT1, VEGFA ADRA1D 2074/4885ADRA1A 2284/4885ADRA1B 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.